Euroapi

Euroapi Profit per Employee

The Profit per Employee of Euroapi (EAPI.PA) as of Oct 30, 2026 is -61,235.14 EUR. In the previous year, Profit per Employee was -37,866.05 EUR — a change of 61.72% (lower).

Profit per Employee

-61,235.14EUR

YoY

61.72%

Last updated:

Profit per Employee of Euroapi is 2025 -61,235.14 EUR. Profit per Employee of Euroapi was 2024 -37,866.05 EUR. It decreases by 61.72% lower compared to the previous year.

The Euroapi Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2019
724.85 EUR
Jan 1, 2020
-1,826.62 EUR
Jan 1, 2021
-2,348.51 EUR
Jan 1, 2022
-4,349.09 EUR
Jan 1, 2023
-55,001.45 EUR
Jan 1, 2024
-37,866.05 EUR
Jan 1, 2025
-61,235.14 EUR
The Euroapi Profit per Employee history
YEARProfit per EmployeeYoY
-61,235.14EUR+61.72%
-37,866.05EUR-31.15%
-55,001.45EUR+1,164.67%
-4,349.09EUR+85.19%
-2,348.51EUR+28.57%
-1,826.62EUR-352.00%
724.85EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Euroapi Stock analysis

What does Euroapi do? Euroapi SA generates revenue by manufacturing and supplying active pharmaceutical ingredient solutions to healthcare companies. The company develops and produces vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, hormones, anti-infectives, opiates including morphine, codeine, and thebaine, as well as analgesics. It offers Contract Development and Manufacturing Organization (CDMO) services through its Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones, and Opiates & Controlled Substances technologies. Healthcare partners purchase these products and services, with production sites across France, the United Kingdom, Germany, Italy, and Hungary supporting the supply chain. The company’s primary customers are healthcare companies seeking active pharmaceutical ingredient solutions. These clients buy products like vitamin B12, prostaglandins, and opiates, as well as CDMO services such as Microbial Fermentation and Steroids and Hormones development. Euroapi SA’s revenue streams are derived from both the direct sale of active ingredients and the provision of specialized manufacturing services through its CDMO division. Euroapi SA’s business model relies on its global production network in five countries to deliver tailored pharmaceutical solutions. The firm’s portfolio includes high-demand molecules such as opioids (morphine, codeine, thebaine) and hormone-based treatments, which are supplied to healthcare partners through its CDMO services. This dual approach of product sales and service-based manufacturing ensures steady revenue from established pharmaceutical markets. Euroapi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Euroapi stock

Profit per Employee of Euroapi is -61,235.14 EUR in 2025.

Profit per Employee of Euroapi changed from -37,866.05 EUR to -61,235.14 EUR, representing a 61.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Euroapi since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Euroapi historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Euroapi

All Key Metrics — Euroapi